Truist maintains Buy rating on Jazz Pharmaceuticals
Benzinga reports Truist Securities maintained a Buy rating on Jazz Pharmaceuticals.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Truist maintains Jazz Pharmaceuticals buy; raises price target
Truist Securities maintained a Buy on Jazz Pharmaceuticals and raised its price target to $286 from $281, per Benzinga ratings coverage.